Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Tumour-elicited neutrophils engage mitochondrial metabolism to circumvent nutrient limitations and maintain immune suppression.

Rice CM, Davies LC, Subleski JJ, Maio N, Gonzalez-Cotto M, Andrews C, Patel NL, Palmieri EM, Weiss JM, Lee JM, Annunziata CM, Rouault TA, Durum SK, McVicar DW.

Nat Commun. 2018 Nov 30;9(1):5099. doi: 10.1038/s41467-018-07505-2.

2.

Serum-based tracking of de novo initiated liver cancer progression reveals early immunoregulation and response to therapy.

Subleski JJ, Scarzello AJ, Alvord WG, Jiang Q, Stauffer JK, Kronfli A, Saleh B, Back T, Weiss JM, Wiltrout RH.

J Hepatol. 2015 Nov;63(5):1181-9. doi: 10.1016/j.jhep.2015.06.021. Epub 2015 Jul 2.

3.

Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/αCD40 therapy.

Weiss JM, Subleski JJ, Back T, Chen X, Watkins SK, Yagita H, Sayers TJ, Murphy WJ, Wiltrout RH.

J Immunol. 2014 Jun 15;192(12):5821-9. doi: 10.4049/jimmunol.1400404. Epub 2014 May 7.

4.

IFN-gamma AU-rich element removal promotes chronic IFN-gamma expression and autoimmunity in mice.

Hodge DL, Berthet C, Coppola V, Kastenmüller W, Buschman MD, Schaughency PM, Shirota H, Scarzello AJ, Subleski JJ, Anver MR, Ortaldo JR, Lin F, Reynolds DA, Sanford ME, Kaldis P, Tessarollo L, Klinman DM, Young HA.

J Autoimmun. 2014 Sep;53:33-45. doi: 10.1016/j.jaut.2014.02.003. Epub 2014 Feb 28.

5.

Systemic IL-12 administration alters hepatic dendritic cell stimulation capabilities.

Chan T, Back TC, Subleski JJ, Weiss JM, Ortaldo JR, Wiltrout RH.

PLoS One. 2012;7(3):e33303. doi: 10.1371/journal.pone.0033303. Epub 2012 Mar 13.

6.

The split personality of NKT cells in malignancy, autoimmune and allergic disorders.

Subleski JJ, Jiang Q, Weiss JM, Wiltrout RH.

Immunotherapy. 2011 Oct;3(10):1167-84. doi: 10.2217/imt.11.117. Review.

7.

TCR-dependent and -independent activation underlie liver-specific regulation of NKT cells.

Subleski JJ, Hall VL, Wolfe TB, Scarzello AJ, Weiss JM, Chan T, Hodge DL, Back TC, Ortaldo JR, Wiltrout RH.

J Immunol. 2011 Jan 15;186(2):838-47. doi: 10.4049/jimmunol.1001735. Epub 2010 Dec 10.

8.

Expression of costimulatory TNFR2 induces resistance of CD4+FoxP3- conventional T cells to suppression by CD4+FoxP3+ regulatory T cells.

Chen X, Hamano R, Subleski JJ, Hurwitz AA, Howard OM, Oppenheim JJ.

J Immunol. 2010 Jul 1;185(1):174-82. doi: 10.4049/jimmunol.0903548. Epub 2010 Jun 4.

9.

Co-expression of TNFR2 and CD25 identifies more of the functional CD4+FOXP3+ regulatory T cells in human peripheral blood.

Chen X, Subleski JJ, Hamano R, Howard OM, Wiltrout RH, Oppenheim JJ.

Eur J Immunol. 2010 Apr;40(4):1099-106. doi: 10.1002/eji.200940022.

10.

Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment.

Weiss JM, Back TC, Scarzello AJ, Subleski JJ, Hall VL, Stauffer JK, Chen X, Micic D, Alderson K, Murphy WJ, Wiltrout RH.

Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19455-60. doi: 10.1073/pnas.0909474106. Epub 2009 Nov 5.

11.

Editorial: NKT cells: to suppress or not to suppress, that is the question.

Subleski JJ, Ortaldo JR.

J Leukoc Biol. 2009 Oct;86(4):751-2. doi: 10.1189/jlb.0309118. No abstract available.

12.

Application of tissue-specific NK and NKT cell activity for tumor immunotherapy.

Subleski JJ, Wiltrout RH, Weiss JM.

J Autoimmun. 2009 Nov-Dec;33(3-4):275-81. doi: 10.1016/j.jaut.2009.07.010. Epub 2009 Aug 13. Review.

13.

Interleukin-15 enhances proteasomal degradation of bid in normal lymphocytes: implications for large granular lymphocyte leukemias.

Hodge DL, Yang J, Buschman MD, Schaughency PM, Dang H, Bere W, Yang Y, Savan R, Subleski JJ, Yin XM, Loughran TP Jr, Young HA.

Cancer Res. 2009 May 1;69(9):3986-94. doi: 10.1158/0008-5472.CAN-08-3735. Epub 2009 Apr 14.

14.
15.

Multiprobe ribonuclease protection assay for simultaneous measurement of mRNA expression.

Young HA, Subleski JJ, Krebs SM.

Curr Protoc Immunol. 2003 Aug;Chapter 10:Unit 10.29. doi: 10.1002/0471142735.im1029s54. Review.

PMID:
18432896
16.

Immunotherapy of cancer by IL-12-based cytokine combinations.

Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH.

Expert Opin Biol Ther. 2007 Nov;7(11):1705-21. Review.

17.

Enhanced antitumor response by divergent modulation of natural killer and natural killer T cells in the liver.

Subleski JJ, Hall VL, Back TC, Ortaldo JR, Wiltrout RH.

Cancer Res. 2006 Nov 15;66(22):11005-12.

18.

The proinflammatory cytokine interleukin-18 alters multiple signaling pathways to inhibit natural killer cell death.

Hodge DL, Subleski JJ, Reynolds DA, Buschman MD, Schill WB, Burkett MW, Malyguine AM, Young HA.

J Interferon Cytokine Res. 2006 Oct;26(10):706-18.

PMID:
17032165
19.

Peroxisome proliferator-activated receptor-gamma and its ligands attenuate biologic functions of human natural killer cells.

Zhang X, Rodriguez-Galán MC, Subleski JJ, Ortaldo JR, Hodge DL, Wang JM, Shimozato O, Reynolds DA, Young HA.

Blood. 2004 Nov 15;104(10):3276-84. Epub 2004 Jul 20.

PMID:
15265789

Supplemental Content

Loading ...
Support Center